Retrospective Study
Copyright ©The Author(s) 2022.
World J Gastrointest Surg. Sep 27, 2022; 14(9): 940-949
Published online Sep 27, 2022. doi: 10.4240/wjgs.v14.i9.940
Table 1 Differences between the demographic and clinical characteristics of the recurrence and nonrecurrence groups
Demographic characteristicsn (%)
Recurrence (n = 13)
Nonrecurrence (n = 117)
Total (n = 130)
Age (yr)
< 608 (61.5)62 (54.0)70 (53.8)
≥ 605 (38.5)55 (47.0)60 (46.2)
Sex
Male6 (46.2)61 (52.1)67 (51.5)
Female7 (53.8)56 (47.9)63 (48.5)
Tumor site
Stomach9 (69.2)92 (78.6)101 (77.7)
Small intestine1 (7.7)23 (19.7)24 (18.5)
Large intestine3 (23.1)2 (1.7)5 (3.8)
Tumor size
< 2 cm2 (15.4)25 (21.4)27 (20.8)
≥ 2 and ≤ 5 cm6 (46.1)56 (47.9)62 (47.7)
> 5 and ≤ 10 cm1 (7.7)30 (25.6)31 (23.8)
> 10 cm4 (30.8)6 (5.1)10 (7.7)
NIH risk category
Very low3 (23.1)31 (26.5)34 (26.2)
Low2 (15.4)31 (26.5)33 (25.4)
Middle1 (7.7)27 (23.1)28 (21.5)
High7 (53.8)28 (23.9)35 (26.9)
Mitotic rate
≤ 5 cm7 (53.8)87 (74.4)94 (72.3)
> 5 cm and ≤ 10 cm2 (15.4)22 (18.8)24 (18.5)
> 10 cm4 (30.8)8 (6.8)12 (9.2)
Ki-67
< 5% 4 (30.8)70 (59.8)74 (56.9)
≥ 5% 9 (69.2)47 (40.2)56 (43.1)
Intratumoral hemorrhage
Yes10 (76.9)100 (85.5)110 (84.6)
No3 (23.1)17 (14.5)20 (15.4)
Intratumoral necrosis
Yes8 (61.5)99 (84.6)107 (82.3)
No5 (38.5)18 (15.4)23 (17.7)
Table 2 Prediction factors for recurrence of gastrointestinal stromal tumor
Intercept and variablePrediction model
β
Odds ratio (95%CI)
P value
Intercept -3.00920.049 (0.006-0.245)0.001
Mitotic rate3.215224.907 (2.215-707.556)0.020
Ki-670.75142.120 (0.340-15.083)0.425
Intratumoral necrosis-0.26750.765 (0.081-5.421)0.799
Tumor size -0.01470.985 (0.115-10.405)0.989
Tumor site3.411530.313 (3.265-405.088)0.003
Age0.10481.110 (0.228-5.611)0.895